AZ Centers Pearl As The Jewel Of Its Respiratory Franchise
This article was originally published in The Pink Sheet Daily
Executive Summary
The British pharma announced its proposed acquisition of Pearl Therapeutics, adding a late-stage COPD drug to its pipeline and a triple combo therapy to its mid-stage pipeline.